India pharma deals hold steady at $13.9B
Indian pharma and healthcare deal value held at about $13.9 billion in Q1 FY27 and Q2 2026 despite a decline in deal volumes, led by Sun Pharmaceutical Industries’ $11.8 billion acquisition of Organon & Co. and a clear shift toward specialty portfolios, global market access, and differentiated capabilities, with investor interest centering on AI-enabled care, genomics, oncology, and advanced diagnostics, and outbound M&A accounting for the vast majority of activity.
Health · 5 sources · Jul 23, 2026Read itThe journal
Open the journal →The conversation starts in the journal — be the first to post.
About Sun Pharmaceutical
Sun Pharmaceutical Industries Limited is an Indian multinational pharmaceutical company headquartered in Mumbai. It manufactures and sells pharmaceutical formulations and active pharmaceutical ingredients (APIs) in more than 100 countries. It is the largest pharmaceutical company in India and the fourth largest specialty generic pharmaceutical company in the world.
Everything about Sun Pharmaceutical →- Country
- India
- Headquarters
- Mumbai
- Inception
- 1983
- Website
- http://www.sunpharma.com